Multiple Myeloma Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Multiple myeloma (MM) is a haematological malignancy characterised by the clonal proliferation of plasma cells in the bone marrow, producing a monoclonal protein (M-protein or paraprotein). These malignant plasma cells crowd out normal haematopoiesis, secrete osteoclast-activating factors causing lytic bone lesions, and may cause end-organ damage through direct infiltration or the downstream effects of the M-protein (hypercalcaemia, renal failure).

Epidemiology

Multiple myeloma is the second most common haematological malignancy after non-Hodgkin lymphoma, accounting for approximately 1–2% of all cancers. Median age at diagnosis is 69 years. There is a 2-fold higher incidence in Black/African-American populations compared to White populations. The disease is preceded by asymptomatic precursor states: Monoclonal Gammopathy of Undetermined Significance (MGUS) in approximately 3% of adults over 50, which progresses to smouldering myeloma or active myeloma at 1% per year.

IMWG Diagnostic Criteria — SLiM-CRAB

The International Myeloma Working Group (IMWG) 2014 diagnostic criteria updated the classic 'CRAB' criteria to include three biomarkers of malignancy (SLiM), allowing treatment before end-organ damage occurs:

SLiM criteria (biomarkers of malignancy):

• S — Sixty percent (≥60%) clonal bone marrow plasma cells (BMPCs)
• Li — Light chain ratio: uninvolved/involved serum free light chain ratio ≥100
• M — MRI: >1 focal lesion on whole-body MRI (>5 mm each)

CRAB criteria (end-organ damage):

• C — Calcium elevated >0.25 mmol/L above upper limit of normal, or >2.75 mmol/L
• R — Renal insufficiency: creatinine >177 µmol/L or CrCl <40 mL/min
• A — Anaemia: haemoglobin <100 g/L or >20 g/L below lower limit of normal
• B — Bone lesions: one or more osteolytic lesions on skeletal survey, CT, or PET-CT

Diagnosis requires: clonal BMPCs ≥10% (or biopsy-proven plasmacytoma) plus one or more CRAB or SLiM criteria.

Staging and Cytogenetic Risk

The Revised International Staging System (R-ISS) integrates serum beta-2 microglobulin, albumin, LDH, and high-risk cytogenetics (del(17p), t(4;14), t(14;16)) into three prognostic stages. High-risk cytogenetics are associated with inferior outcomes with standard treatment and influence choice of induction regimen, transplant consolidation, and maintenance intensity.

Monoclonal Gammopathy of Undetermined Significance (MGUS)

MGUS is defined by M-protein <30 g/L, clonal BMPCs <10%, and absence of CRAB/SLiM criteria. No treatment is required; observation with annual M-protein, FLC, and CBC is standard. Risk of progression to symptomatic myeloma is ~1% per year (Mayo Clinic risk model stratified by M-protein type, size, and FLC ratio).

Smouldering Multiple Myeloma (SMM)

SMM has M-protein ≥30 g/L or clonal BMPCs 10–59% without CRAB/SLiM criteria. High-risk SMM (Mayo 20/2/20 model: M-protein ≥20 g/L, FLC ratio ≥20, BMPCs ≥20%) has ~50% risk of progression within 2 years. The QUIREDEX/GEM-CESAR and ECOG E3A06 trials evaluated early lenalidomide-based intervention in high-risk SMM, showing reduced progression to active myeloma.

Newly Diagnosed Multiple Myeloma (NDMM)

Treatment approach is defined by transplant eligibility (age, performance status, comorbidities) and risk stratification (R-ISS, cytogenetics). The majority of newly diagnosed patients undergo induction chemotherapy followed by either ASCT consolidation (transplant-eligible) or continued triplet/quadruplet therapy (transplant-ineligible).

Relapsed/Refractory Multiple Myeloma (RRMM)

Despite major advances, virtually all patients relapse. The number of prior lines of therapy, prior drug exposure (PI, IMiD, anti-CD38 antibody), and renal/cardiac function guide selection of salvage regimens. Patients who are triple-class refractory (refractory to PI + IMiD + anti-CD38 antibody) have limited options with conventional chemotherapy and are candidates for novel BCMA-directed therapies (CAR-T, bispecific antibodies).

Who Is Transplant-Eligible?

Autologous stem cell transplantation (ASCT) following high-dose melphalan conditioning remains a standard consolidation strategy for eligible newly diagnosed patients. Transplant eligibility is determined by:

• Age — traditionally <65 years; extended to <70–75 years with excellent performance status in experienced centres. Biological age is more important than chronological age.
• Performance status — ECOG 0–2 preferred; ECOG 3 considered case-by-case
• Cardiac function — LVEF ≥50% (echocardiogram); history of recent myocardial infarction or severe heart failure is a relative contraindication
• Pulmonary function — DLCO ≥50% predicted (PFTs); restrictive disease from prior infections or amyloidosis may preclude transplant
• Renal function — dialysis-dependent patients can be transplanted at specialist centres with dose-adjusted melphalan; not an absolute contraindication
• Comorbidity index — Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) score guides risk assessment; HCT-CI ≥3 associated with higher non-relapse mortality

Transplant-Ineligible Patients

Approximately 50–60% of newly diagnosed patients are not eligible for ASCT due to age, comorbidity, or patient preference. These patients are treated with continuous triplet (VRd, DRd — daratumumab-lenalidomide-dexamethasone) or quadruplet (Dara-VRd) therapy to best response, followed by lenalidomide maintenance.

Induction Therapy — Transplant-Eligible NDMM

VRd (Bortezomib + Lenalidomide + Dexamethasone) — established as standard induction following the SWOG S0777 phase III trial (NEJM 2017), which showed VRd superior to Rd (lenalidomide + dexamethasone alone) in PFS (43 months vs 30 months) and OS (75 months vs 64 months). VRd is administered for 4–6 cycles prior to stem cell mobilisation and ASCT. Subcutaneous bortezomib (ASCO 2011 meta-analysis) has equivalent efficacy with significantly lower peripheral neuropathy rates than intravenous administration.

Daratumumab-Based Quadruplets — The New Standard of Care

• Dara-VRd (GRIFFIN trial, NEJM Evid 2023) — daratumumab + bortezomib + lenalidomide + dexamethasone vs VRd in transplant-eligible NDMM; superior sCR (stringent complete response) rate (46% vs 42%) and MRD negativity at 12 months post-ASCT (62.5% vs 27.2%)
• Dara-VRd (PERSEUS trial, NEJM 2024) — phase III trial (722 patients) confirmed Dara-VRd superiority: 48-month PFS rate 84.3% vs 67.7% for VRd alone; MRD negativity at 10⁻⁵ sensitivity: 75.2% vs 47.5%; Dara-VRd is increasingly adopted as the preferred quadruplet induction in transplant-eligible patients at major myeloma centres.
• Isa-KRd (isatuximab + carfilzomib + lenalidomide + dexamethasone) — GMMG-CONCEPT trial showed high MRD negativity rates in high-risk cytogenetic myeloma; under investigation as an alternative for high-risk disease.

Autologous Stem Cell Transplant (ASCT)

Following 4–6 cycles of induction, stem cells are mobilised with G-CSF ± plerixafor and collected by apheresis (target: ≥4–6 × 10⁶ CD34+ cells/kg). High-dose melphalan conditioning (200 mg/m² — reduced to 140 mg/m² in renal impairment) is followed by autologous stem cell infusion. Engraftment (ANC >0.5 × 10⁹/L) typically occurs at day 10–14. ASCT reduces the myeloma burden and achieves deepening of response achieved with induction.

Tandem ASCT — a planned second ASCT 3–6 months after the first; improves PFS in standard-risk patients who achieve less than VGPR (very good partial response) after first ASCT (EMN02/HO95 trial); increasingly reserved for patients not achieving MRD negativity after first ASCT.

Maintenance Therapy

• Lenalidomide maintenance — two landmark RCTs (IFM 2005-02 and CALGB 100104) established lenalidomide maintenance post-ASCT as standard of care, improving PFS by 18–24 months vs placebo. Meta-analysis (McCarthy NEJM 2012) showed OS benefit. Continued until disease progression or intolerance. Risk of second primary malignancies (~4% excess at 4 years) is offset by survival benefit.
• Bortezomib maintenance — preferred in high-risk cytogenetics (del17p, t[4;14]) where lenalidomide maintenance alone is insufficient; HOVON-65/GMMG-HD4 demonstrated benefit of bortezomib-based maintenance in high-risk disease.
• Daratumumab maintenance — post-ASCT daratumumab + lenalidomide maintenance (AURIGA trial — results 2024) shows deepening of MRD negativity rates; likely to become standard in patients receiving Dara-VRd induction.

Transplant-Ineligible NDMM

• DRd (Daratumumab + Lenalidomide + Dexamethasone) — MAIA trial (NEJM 2019): DRd vs Rd; at 5 years, median PFS not yet reached with DRd vs 34.4 months with Rd; OS advantage confirmed at extended follow-up. DRd is the standard of care for transplant-ineligible NDMM.
• Dara-VMP (Daratumumab + Bortezomib + Melphalan + Prednisone) — ALCYONE trial; PFS and OS benefit confirmed; alternative for patients in whom lenalidomide is not preferred (significant renal impairment at baseline).

Relapsed/Refractory Myeloma (RRMM) — Treatment by Line

Second and Third Line:

• Carfilzomib-based regimens — KRd (carfilzomib + lenalidomide + dexamethasone; ASPIRE trial) or Kd (ENDEAVOR trial) for PI-sensitive relapse
• Pomalidomide-based regimens — Pd (pomalidomide + dexamethasone; MM-003) or DPd (daratumumab + pomalidomide + dexamethasone; APOLLO) for IMiD-sensitive or lenalidomide-refractory disease
• Isatuximab-Kd — IKEMA trial (isatuximab + carfilzomib + dexamethasone): PFS 35.7 vs 19.2 months vs Kd at 44-month follow-up; now NCCN category 1 for RRMM

BCMA-Directed Therapies for Triple-Class Refractory RRMM:

• Idecabtagene vicleucel (ide-cel; Abecma) — anti-BCMA CAR-T cell therapy; KarMMa trial (NEJM 2021): ORR 73%, sCR 33%, median PFS 8.8 months in heavily pre-treated RRMM (median 6 prior lines). FDA-approved 2021.
• Ciltacabtagene autoleucel (cilta-cel; Carvykti) — LCAR-B38M FMC63-based anti-BCMA CAR-T; CARTITUDE-1 trial (Lancet Oncol 2022): ORR 98%, sCR 83%, 18-month PFS 66%; superior depth of response vs ide-cel; FDA-approved March 2022. Moving earlier in disease course in CARTITUDE-4 (vs standard salvage at 1–3 prior lines).
• Teclistamab (Tecvayli) — BCMA × CD3 bispecific antibody; MajesTEC-1 trial (NEJM 2022): ORR 63%, sCR 39.4%, median PFS 11.3 months in triple-class refractory RRMM; FDA-approved 2022; no cell manufacturing required — advantage over CAR-T for rapidly progressing disease.
• Elranatamab (Elrexfio) — BCMA × CD3 bispecific antibody; MagnetisMM-3: ORR 61% in BCMA-naive triple-class refractory RRMM; FDA-approved August 2023.
• Belantamab mafodotin (Blenrep) — anti-BCMA antibody-drug conjugate; ORR ~31% in heavily pre-treated RRMM; associated with ocular toxicity (keratopathy in ~70%; requires regular ophthalmology monitoring); re-evaluated in combination regimens.

Minimal Residual Disease (MRD) as Treatment Endpoint

MRD assessment is rapidly becoming the primary surrogate endpoint in myeloma trials, replacing conventional response criteria (CR/sCR). Methods:

• Next-generation sequencing (NGS) — clonoSEQ (Adaptive Biotechnologies): sensitivity 10⁻⁵ to 10⁻⁶ (1 myeloma cell in 100,000–1,000,000 marrow cells); FDA-cleared for MRD assessment in myeloma and ALL
• Next-generation flow cytometry (EuroFlow) — 8-colour multiparameter flow cytometry; sensitivity 10⁻⁵; standardised across European HOVON-EMN network
• MRD negativity sustained for ≥12 months is associated with significantly prolonged PFS and OS across transplant-eligible and ineligible settings; IMWG MRD consensus criteria published Leukemia 2016

MRD-guided treatment adaptation (extending or stopping maintenance based on sustained MRD negativity) is being evaluated in the DRAMMATIC, IsKia, and REMNANT studies.

Multiple myeloma outcomes have transformed dramatically over the past two decades with the introduction of novel agents:

• 1990s (alkylating agent era) — median overall survival ~3 years
• 2000s (IMiD + PI era) — median OS increased to 5–7 years for transplant-eligible patients
• 2010s (anti-CD38 antibody era) — median OS ~8–10 years for transplant-eligible patients with standard-risk cytogenetics
• 2020s (BCMA-directed therapies, MRD-guided care) — PFS rates at 4 years approaching 80–85% with Dara-VRd quadruplet + ASCT + maintenance (PERSEUS); OS curves continue improving

Survival by Risk Group (Current Data)

• Standard-risk NDMM — median OS >10 years; functional cure (sustained MRD negativity >10 years) achievable in a subset of patients
• High-risk cytogenetics (del17p, t[4;14]) — median OS 4–6 years despite modern therapy; requires clinical trial enrolment
• ISS III (high-risk by LDH + cytogenetics) — median OS 29 months (R-ISS III); intensified quadruplet regimens + tandem ASCT being evaluated

Quality of Life

Modern myeloma therapy is increasingly delivered with subcutaneous formulations (daratumumab SC [COLUMBA trial] and bortezomib SC) and oral agents (lenalidomide, pomalidomide, ixazomib), reducing clinic visit burden. Lenalidomide maintenance is generally well-tolerated; primary toxicities are fatigue, myelosuppression, and DVT (requires thromboprophylaxis). Long-term neurotoxicity from bortezomib is managed by SC route and dose adjustment.

Bortezomib (Velcade)

• Peripheral neuropathy — most important cumulative toxicity; incidence significantly lower with SC vs IV administration (38% vs 53% any grade; 24% vs 41% grade 2+; ASCO abstract 2011). Management: dose reduction, hold, or switch to carfilzomib.
• Myelosuppression, nausea, diarrhoea, fatigue. VZV reactivation — all PI-treated patients require antiviral prophylaxis (aciclovir/valaciclovir).

Lenalidomide (Revlimid)

• Venous thromboembolism (DVT/PE) — IMiD-mediated thrombosis; all patients require thromboprophylaxis (aspirin for low-risk, LMWH or rivaroxaban for high-risk)
• Myelosuppression, fatigue, rash, diarrhoea, dose-related renal toxicity
• Second primary malignancies — ~1–2% absolute excess risk with long-term maintenance; most commonly AML and solid tumours; risk-benefit favours lenalidomide maintenance given survival benefit
• Teratogenicity (Category X) — strict pregnancy prevention programme (REMS in USA, EUDRISK in EU) mandatory

Daratumumab

• Infusion-related reactions (IRR) — occur in 30–50% during first infusion; premedication with methylprednisolone, antihistamine, and paracetamol mandatory; SC formulation (co-formulated with hyaluronidase) reduces IRR to <10%
• Interference with blood bank crossmatch — daratumumab binds CD38 on red blood cells, causing panagglutination; all patients require blood bank notification and phenotyping before treatment
• Upper respiratory tract infections increased vs control arms

ASCT-Specific Risks

• Transplant-related mortality (TRM): 1–2% at experienced centres with modern supportive care
• Engraftment syndrome, mucositis, sepsis during neutropenic phase
• CMV reactivation — monitoring and pre-emptive therapy with ganciclovir/valganciclovir
• Melphalan-induced infertility — all patients of reproductive age should be counselled about fertility preservation prior to ASCT

CAR-T and Bispecific Antibody Toxicities

• Cytokine Release Syndrome (CRS) — occurs in 70–90% of CAR-T recipients; managed per ASTCT CRS grading criteria; tocilizumab (IL-6 receptor blockade) is first-line for grade ≥2 CRS
• Neurotoxicity (ICANS) — immune effector cell-associated neurotoxicity; close neurological monitoring during CAR-T infusion period mandatory; corticosteroids for grade ≥2
• Prolonged cytopenias — especially after cilta-cel; haematological toxicity can persist for months; G-CSF, transfusion support required
• Infections — severe and prolonged hypogammaglobulinaemia after anti-BCMA therapies; monthly IVIG supplementation recommended; Pneumocystis, antifungal, and antiviral prophylaxis required
• Ocular toxicity (belantamab) — corneal epithelial changes requiring specialist ophthalmological monitoring with every 3-week cycle

Response Assessment Schedule

IMWG response criteria (sCR, CR, VGPR, PR, SD, PD) are assessed by:

• Serum protein electrophoresis (SPEP) and immunofixation (IFE) — M-protein quantification
• Serum free light chains (FLC) — essential for non-secretory or light-chain-only myeloma
• 24-hour urine protein electrophoresis (UPEP) and IFE — urine M-protein
• Bone marrow biopsy — morphological plasma cell percentage; required for CR/sCR assessment and MRD testing
• Whole-body low-dose CT or PET-CT — bone disease response and new lesions; PET-CT preferred in clinical trials and progressive disease assessment

MRD Monitoring

At institutions practising MRD-guided care, bone marrow MRD assessment (NGS or flow) is performed:

• After induction (pre-ASCT)
• Day 100 post-ASCT
• 12 months post-ASCT
• Annually during maintenance, or when clinical/biochemical change suggests progression

Sustained MRD negativity (>12 months) in patients on lenalidomide maintenance is being evaluated in treatment discontinuation trials; outside trials, maintenance is currently continued until progression or intolerance.

Surveillance for Complications

• Bone disease — bisphosphonates (zoledronic acid monthly × 2 years, then every 3 months; ASCO guidelines); denosumab alternative for renal impairment
• Infection prophylaxis — all PI-treated patients: VZV prophylaxis; all daratumumab-treated patients: PCP prophylaxis (co-trimoxazole); annual influenza and pneumococcal vaccination; IVIG supplementation if recurrent infections or IgG <4 g/L
• Renal monitoring — creatinine and eGFR at each visit; hydration guidance; avoid NSAIDs and iodinated contrast
• Second primary malignancies — annual skin examination; appropriate cancer screening per age/gender guidelines

Haematology Follow-Up Frequency

Patients on active treatment are reviewed by haematology every 4–8 weeks. Patients on maintenance only (lenalidomide) after achieving MRD negativity are typically reviewed every 3 months with biochemical monitoring every 4–6 weeks. After treatment discontinuation (in trial settings), monthly biochemical monitoring for 12 months, then every 3 months.

Treatment costs for Multiple Myeloma Treatment vary significantly by procedure complexity, healthcare system, and geographic location. In India — the leading global medical tourism destination — major procedures cost 60–85% less than comparable treatment in the USA or UK while maintaining equivalent or superior clinical outcomes at NABH- or JCI-accredited facilities. Consultation and diagnostic workup: $30–200 India vs $500–3,000 USA. Inpatient procedures: $1,000–10,000 India vs $10,000–80,000 USA. Medications and ongoing management: generic drugs available in India at 80–95% lower cost than branded equivalents in the USA. Follow-up imaging and laboratory monitoring: 70–85% cost savings in India. Medical tourism packages (including treatment, accommodation, and local logistics support) are offered by major Indian hospital groups (Apollo, Fortis, Medanta, Narayana Health, Manipal Hospitals). For patients from high-income countries, medical tourism to India, Thailand, or Turkey for elective procedures can achieve savings of $10,000–200,000 per episode while accessing care from internationally trained specialists.

Next-Generation BCMA-Directed Therapies

The BCMA (B-Cell Maturation Antigen) space continues to expand rapidly:

• Alnuctamab — BCMA × CD3 bispecific; BMS-986349; phase II results pending; differentiated dosing schedule
• Linvoseltamab — BCMA × CD3 bispecific (LINKER-MM1 trial); weekly subcutaneous dosing
• GPRC5D-directed bispecific antibodies — talquetamab (GPRC5D × CD3; MonumenTAL-1 trial: ORR 74% in heavily pre-treated RRMM; FDA-approved 2023); provides an option after BCMA exposure
• FcRH5-directed bispecific — cevostamab (FCRL5 × CD3); active in BCMA-pre-treated RRMM

Allogenic CAR-T and Off-the-Shelf Cell Therapies

Current approved CAR-T products (ide-cel, cilta-cel) are autologous (patient's own T-cells), requiring 3–6 months manufacturing. Allogeneic CAR-T (using donor T-cells) could be manufactured in advance and administered like a drug — critical for patients with rapidly progressing disease. Clinical trials are ongoing; efficacy comparable to autologous CAR-T has not yet been established.

Venetoclax for t(11;14) Myeloma

t(11;14) translocation (present in ~15–20% of myeloma) drives BCL-2 overexpression. Venetoclax (BCL-2 inhibitor) as monotherapy or combined with bortezomib-dex (BELLINI trial) achieves impressive responses specifically in t(11;14) patients, a biomarker-driven treatment approach. FDA Breakthrough Therapy designation received; Phase III CANOVA trial ongoing.

Selinexor (Nuclear Export Inhibitor)

Selinexor (Xpovio) — selective inhibitor of nuclear export (SINE) targeting exportin-1 (XPO1); STORM trial (NEJM 2019): ORR 26% in penta-refractory RRMM; approved as combination therapy (selinexor-bortezomib-dex in BOSTON trial: PFS 13.9 vs 9.5 months vs Vd). Weekly dosing reduces nausea compared to twice-weekly scheduling.

Quadruplet Regimens Moving Earlier

Results from PERSEUS and GRIFFIN suggest that achieving deep MRD negativity upfront (with quadruplet induction) is the optimal strategy. Clinical trials exploring MRD-guided intensification (adding a 4th agent for MRD-positive patients), MRD-guided discontinuation (stopping maintenance in sustained MRD-negative patients), and consolidation ASCT avoidance in MRD-negative quadruplet-treated patients will reshape treatment algorithms over the next 5–10 years.